Compare IZEA & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IZEA | BTAI |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.1M | 49.2M |
| IPO Year | N/A | 2018 |
| Metric | IZEA | BTAI |
|---|---|---|
| Price | $4.86 | $2.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.80 |
| AVG Volume (30 Days) | 171.2K | ★ 658.3K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $36,176,492.00 | $752,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.91 | $544.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.12 | N/A |
| 52 Week Low | $1.68 | $1.17 |
| 52 Week High | $5.86 | $9.26 |
| Indicator | IZEA | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 48.54 | 51.76 |
| Support Level | $4.78 | $1.82 |
| Resistance Level | $5.15 | $2.33 |
| Average True Range (ATR) | 0.28 | 0.17 |
| MACD | -0.03 | 0.05 |
| Stochastic Oscillator | 18.11 | 62.87 |
IZEA Worldwide Inc offers solutions that range from creator agency services to creator technologies to a marketplace that connects marketers with creators. The Company provides value through managing custom content workflow, creator search and targeting, bidding, analytics, and payment processing. The company also enables creators to monetize their content, creativity, and influence through brands and marketers. The company compensates these creators for producing content, such as long and short-form text, videos, photos, status updates, and illustrations, for marketers or distributing such content on behalf of marketers through their websites, blogs, and social media channels.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.